Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.

MLA

Negrier, M. S., et al. “Phase I Trial of Recombinant Interleukin-2 Followed by Recombinant Tumor Necrosis Factor in Patients with Metastatic Cancer.” Journal of Immunotherapy : Official Journal of the Society for Biological Therapy, vol. 11, no. 2, Feb. 1992, pp. 93–102. EBSCOhost, https://doi.org/10.1097/00002371-199202000-00003.

APA

Negrier, M. S., Pourreau, C. N., Palmer, P. A., Ranchere, J. Y., Mercatello, A., Viens, P., Blaise, D., Jasmin, C., Misset, J. L., Franks, C. R., & et. al. (1992). Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. Journal of Immunotherapy : Official Journal of the Society for Biological Therapy, 11(2), 93–102. https://doi.org/10.1097/00002371-199202000-00003

Chicago

Negrier, M S, C N Pourreau, P A Palmer, J Y Ranchere, A Mercatello, P Viens, D Blaise, et al. 1992. “Phase I Trial of Recombinant Interleukin-2 Followed by Recombinant Tumor Necrosis Factor in Patients with Metastatic Cancer.” Journal of Immunotherapy : Official Journal of the Society for Biological Therapy 11 (2): 93–102. doi:10.1097/00002371-199202000-00003.